Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer

被引:15
|
作者
Xu, Jian-Lun [1 ]
Commins, John [2 ]
Partridge, Edward [3 ]
Riley, Thomas L. [2 ]
Prorok, Philip C. [1 ]
Johnson, Christine C. [4 ]
Buys, Saundra S. [5 ]
机构
[1] NCI, Biometry Res Grp, Bethesda, MD 20892 USA
[2] Informat Management Serv Inc, Rockville, MD USA
[3] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[4] Henry Ford Hlth Syst, Detroit, MI USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
关键词
CA-125; Ovarian cancer; Screening; Velocity; LOGISTIC-REGRESSION ANALYSIS; PROGNOSTIC MODELS; SERUM CA-125; PROSTATE; LUNG;
D O I
10.1016/j.ygyno.2011.12.440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer. Methods. In the ovarian component of the PLCO cancer screening trial, 28,038 women aged 55-74 had at least two CA-125 screening tests. Ovarian cancer was diagnosed in 72 (0.26%) women. A multiple logistic regression model was developed to evaluate CA-125 velocity and other related covariates as predictors of ovarian cancer. Predictive accuracy was assessed by the concordance index and measures of discrimination and calibration while the fit of the model was assessed by the Hosmer and Lemeshow's goodness-of-fit chi(2) test. Results. CA-125 velocity decreased as the number of CA-125 measurements increased but was unaffected by age at baseline screen and family history of ovarian cancer. The average velocity (19.749 U/ml per month) of the cancer group was more than 500 times the average velocity (0.035 U/ml per month) of the non-cancer group. Conclusion. Among six covariates used in the model, CA-125 velocity and time intervals between baseline and second to last screening test and between last two screening tests were statistically significant predictors of ovarian cancer. The chance of having ovarian cancer increased as velocity increased, and the chance decreased when the time intervals between baseline and the second to last screening test and between last two screening tests of an individual increased. Published by Elsevier Inc.
引用
收藏
页码:70 / 74
页数:5
相关论文
共 50 条
  • [1] CA-125 criteria for response evaluation in ovarian cancer
    Sundar, S
    O'byrne, KJ
    GYNECOLOGIC ONCOLOGY, 2005, 98 (03) : 520 - 521
  • [2] EVALUATION OF CA-125 AS A MARKER IN OVARIAN-CANCER
    DUFFY, MJ
    DAVIS, MA
    SHEEHAN, J
    FENNELLY, JJ
    CLINICAL CHEMISTRY, 1988, 34 (06) : 1293 - 1293
  • [3] SERUM CA-125 AND PREDICTION OF OUTCOME IN OVARIAN-CANCER
    REDMAN, CWE
    BLACKLEDGE, GRP
    BUXTON, EJ
    LAWTON, FG
    LUESLEY, DM
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (08): : 749 - 749
  • [4] CA-125 IN OVARIAN-CANCER
    VANDERBURG, MEL
    LAMMES, FB
    VERWEIJ, J
    NETHERLANDS JOURNAL OF MEDICINE, 1992, 40 (1-2): : 36 - 51
  • [5] A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer
    Chiang, An Jen
    Chen, Jiabin
    Chung, Yu-He
    Huang, Huan-Jung
    Liou, Wen Shiung
    Chang, Chung
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2014, 25 (01) : 51 - 57
  • [6] SERUM CA-125 IN EPITHELIAL OVARIAN-CANCER - A LONGITUDINAL-STUDY
    BRIOSCHI, PA
    IRION, O
    BISCHOF, P
    BADER, M
    FORNI, M
    KRAUER, F
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1987, 94 (03): : 196 - 201
  • [7] OVARIAN-CANCER, INFLAMMATION, AND CA-125
    MARKMAN, M
    HOSKINS, WB
    ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) : 1049 - 1049
  • [8] USE OF CA-125 IN THE MANAGEMENT OF OVARIAN CANCER
    Mahner, S.
    Sehouli, J.
    Woelber, L.
    Jaenicke, F.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4033 - 4034
  • [9] CA-125 AND SURVIVAL IN OVARIAN-CANCER
    PARKER, D
    PATEL, K
    ALRED, EJ
    HARNDENMAYOR, P
    NAYLOR, B
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1988, 81 (01) : 22 - 22
  • [10] CA-125 AND SURVIVAL IN OVARIAN-CANCER
    PARKER, D
    PATEL, K
    ALRED, J
    HARNDENMAYOR, P
    NAYLOR, B
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 233 - 234